EUVIMEDEUVIMED entdecken
Crossref

Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!

Islam A S Elhelf, Michael Clemenshaw

Nuklearmedizin - NuclearMedicine · 2025-12 · 64 (06) · 352-355

DOI: 10.1055/a-2729-8686 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, online erschienen am 26.11.2025. Verfasst von Islam A S Elhelf und 1 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Radiology, Department of Radiology, Medical College of Georgia, Augusta University, Augusta, Georgia. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Radiology, Interventional. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2018, the Food and Drug Administration (FDA) approved lutetium-177 (177Lu) DOTATATE (LUTATHERA, Advanced Accelerator Applications [Novartis]) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Since then, 177Lu DOTATATE has been increasingly used as a treatment option for NETs. Less than 5 years later, in March 2022, 177Lu vipivotide tetraxetan (PLUVICTO, Advanced Accelerator Applications) received FDA approval for the treatment of prostatespecific membrane antigen-positive castration-resistant metastatic prostate cancer. Both drugs are excellent examples of viable radiotheranostic therapies. As more radiotheranostic agents and applications get adopted in clinical practice, interventional radiologists are likely to get exposed to this field in a way or another. In this article, we discuss the fundamentals of radiotheranostic therapy and explore the expanding role interventional radiology (IR) is expected to play as an essential partner in modern oncology practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotideRadiology, InterventionalHumansPancreatic NeoplasmsRadiopharmaceuticalsOrganometallic Compounds

Substanzen

lutetium Lu 177 dotatateOctreotideRadiopharmaceuticalsOrganometallic Compounds

Autor:innen und Institutionen

  • Interventional Radiology, Department of Radiology, Medical College of Georgia, Augusta University, Augusta, Georgia.
  • Nuclear Medicine, Department of Radiology, Medical College of Georgia, Augusta University, Augusta, Georgia.

Zitieren

APA

Elhelf, I. A. S., & Clemenshaw, M. (2025). Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!. Nuklearmedizin - NuclearMedicine, 64(06), 352-355. https://doi.org/10.1055/a-2729-8686

Vancouver

Elhelf IAS, Clemenshaw M. Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!. Nuklearmedizin - NuclearMedicine. 2025;64(06):352-355. doi:10.1055/a-2729-8686

BibTeX
@article{Elhelf2025,
  author = {Elhelf, Islam A S and Clemenshaw, Michael},
  title = {Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2025},
  volume = {64},
  number = {06},
  pages = {352--355},
  doi = {10.1055/a-2729-8686}
}
Kostenlos starten →